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Introduction {#sec005}
============

Esophageal cancer (EC) is regarded as one of the most common and fatal malignant tumors in the world. More than 90% of esophageal cancers are esophageal squamous cell carcinomas (ESCCs), which is the most common pathologic type in developing nations \[[@pone.0127304.ref001]\]. ESCC has a relatively high incidence and morbidity in China compared with western countries \[[@pone.0127304.ref002]--[@pone.0127304.ref004]\]. Accumulating epidemiological evidence indicates that tobacco smoking, substantial alcohol intake, micronutrient deficiency, and dietary carcinogen exposure can greatly increase the risk of developing squamous cell carcinoma \[[@pone.0127304.ref005]\]. All these factors can induce or enhance DNA damage, which initiates and/or promotes carcinogenesis. DNA repair has been recognized as the most critical mechanism of protection against DNA damage. Various genes are involved in alcohol-associated carcinogenesis and DNA repair. Single nucleotide polymorphisms (SNPs) in genes such as checkpoint kinase 2 (*CHEK2)* \[[@pone.0127304.ref006]\] and nei endonuclease VIII-like 2 (*NEIL2*) \[[@pone.0127304.ref007]\], which contribute to inter-individual diversity in DNA repair capacity, may play a significant role in modifying EC risk \[[@pone.0127304.ref008]--[@pone.0127304.ref010]\].

The occurrence and development of EC is a multi-stage and multi-factor process involving the accumulation and interaction of various environmental factors and genes. Research on EC-related genes has established that alcohol dehydrogenase 4 (*ADH4)* \[[@pone.0127304.ref011], [@pone.0127304.ref012]\], fibroblast growth factor receptor (*FGFR*) \[[@pone.0127304.ref013]\], thymidylate synthetase (*TYMS*) \[[@pone.0127304.ref014]\], and cyclin-dependent kinase inhibitor 1A (*CDKN1A*) \[[@pone.0127304.ref015], [@pone.0127304.ref016]\] are directly involved in EC to various degrees. Genetic variants of mucin 1 (*MUC1*) \[[@pone.0127304.ref017]\] and S100 calcium binding protein A14 (*S100A14*) \[[@pone.0127304.ref018]\] have been reported to be associated with ESCC. In addition, abnormal expression of ABI family, member 3 binding protein (ABI3BP) \[[@pone.0127304.ref019]\]; klotho beta (KLB) \[[@pone.0127304.ref020]\]; long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) \[[@pone.0127304.ref019]\]; and particular microRNAs, including miR-1206 \[[@pone.0127304.ref020]\] and miR-612 \[[@pone.0127304.ref021]\], has been observed in cancer cells.

Considering the importance of these genes in ESCC, we conducted a large case-control study to estimate the association between 18 potential functional genetic variants of 17 genes and ESCC risk in a discovery dataset (Hangzhou population) and further validated two SNPs in a validation dataset (Jinan population).

Materials and Methods {#sec006}
=====================

Study subjects {#sec007}
--------------

To estimate the frequencies of the alleles and genotypes of newly identified polymorphisms, 617 southern Han Chinese patients with ESCC and 534 sex- and age-matched (±5 years) control subjects were recruited from Zhejiang Cancer Hospital (Hangzhou, Zhejiang Province, China) between January 2012 and November 2013. Control subjects were individuals who were seeking health care in the same hospital for non-oncologic diseases. For the validation arm, 540 northern Han Chinese patients with ESCC were recruited between June 2009 and April 2012 from Shandong Cancer Hospital (Jinan, Shandong Province, China). These patients presented with histologically confirmed ESCC. Five hundred and fifty cancer-free control subjects, randomly selected from a cancer-screening program for the early detection of cancer performed in Jinan city, were frequency-matched to the cancer cases by age (±5 year), gender, and residential area. A short questionnaire was used to obtain demographic and risk factor information, including smoking and alcohol status. Smokers were classified as individuals who smoked once per day for more than one year. Subjects were also defined as alcohol consumers if they ingested alcohol at least once per week. Written informed consent was obtained from all the patients enrolled in this study. The study was approved by the ethics review board of Zhejiang Province Cancer Hospital.

SNP selection and genotyping {#sec008}
----------------------------

We selected SNPs based on their functional potential with a minor allele frequency greater than 0.05 in the Asian population and reviewed related literature to identify potential SNPs that could impact EC.

After signing informed consent forms, each subject donated 5 ml of peripheral blood, which was used for genomic DNA extraction. A Blood Genomic DNA Isolation Kit (Axygen Scientific Inc., CA, USA) was used to extract DNA from leukocyte cell pellets according to the manufacturer's instructions. The DNA purity and concentration were determined by spectrophotometry. All 18 SNPs that were detected at the first stage in the Hangzhou case-control set (discovery set) were also detected using the MassARRAY system (Sequenom Inc., San Diego, California, USA). The genotyping of rs3805322 (*ADH4*) and rs4822983 (*CHEK2*) in the Jinan case-control set was performed using TaqMan assays on an ABI 7900 system (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions. Primers and probes for the two SNPs were supplied by Applied Biosystems. Real-time quantitative polymerase chain reaction (qPCR) was performed under the following conditions: 50°C for 2 minutes, 95°C for 10 minutes, and 45 cycles of 95°C for 30 seconds and 60°C for 1 minute. A random selection of fifteen percent of the samples was reciprocally tested by different persons, and the reproducibility was 99.5%.

Statistical Analysis {#sec009}
--------------------

Differences in gender, age, lifestyle habits and genotype distributions between patients and control subjects were evaluated using Pearson's Chi-Square (X^2^) test. Multiple correction (Bonferroni correction) was used to validate the significant variables. The dominant and recessive models were used to assess the risk of SNP genotypes in EC. The reference group was the minor homozygous genotype among the controls. The associations between two SNPs and the risk of EC were estimated by computing the odds ratios (ORs) and their 95% confidence intervals (CIs) from both univariate and multivariate logistic regression analyses. The ORs were also adjusted for age, gender and smoking status where appropriate. The gene-environment interaction was evaluated by one-way analysis of variance. All the tests were two-sided, and *P* \< 0.05 was considered statistically significant. All the statistical analyses were performed with the SPSS software package (SPSS 18.0 Inc., Chicago, IL, USA).

Results {#sec010}
=======

The clinical characteristics of the discovery dataset (Hangzhou case-control set) and the validation dataset (Jinan case-control set) are listed in **[Table 1](#pone.0127304.t001){ref-type="table"}**. These two case-control sets were used to detect associations between five *ADH1B-ADH1C-ADH7* cluster SNPs and the risk of ESCC \[[@pone.0127304.ref008]\]. There was no difference in the sex or age distribution between ESCC patients and healthy controls for both the Hangzhou and Jinan populations. There were more smokers and alcohol drinkers among the ESCC cases in the Jinan population compared with the controls (both *P* \< 0.05). Unfortunately, no data were collected on the smoking and drinking habits of the controls in the Hangzhou population. The Hardy-Weinberg equilibrium (HWE) values of these 18 SNPs in the Zhejiang set are presented in [Table 2](#pone.0127304.t002){ref-type="table"}. In addition, the *P* values of the HWE tests for rs3805322 (*ADH4*) and rs4822983 (*CHEK2*) in the controls of the Jinan set were 0.495 and 0.873, respectively.

10.1371/journal.pone.0127304.t001

###### Distribution of selected characteristics among ESCC patients and healthy controls.

![](pone.0127304.t001){#pone.0127304.t001g}

  Variable                                                     Hangzhou case-control population   Jinan case-control population                                     
  ------------------------------------------------------------ ---------------------------------- ------------------------------- ------- ------------ ------------ ---------
                                                               617                                534                                     540          550          
  **Age (years)** [^**2**^](#t001fn003){ref-type="table-fn"}                                                                      0.711                             0.167
  **    ≤62 (≤56)**                                            311 (50.4)                         275 (51.5)                              271 (50.2)   299 (54.4)   
  **    \>62 (\>56)**                                          306 (49.6)                         259 (48.5)                              269 (49.8)   251 (45.6)   
  **Sex**                                                                                                                         0.988                             0.193
  **    Male**                                                 534 (86.5)                         462 (86.5)                              428 (79.3)   453 (82.4)   
  **    Female**                                               83 (13.5)                          72 (13.5)                               112 (53.6)   97 (17.6)    
  **Smoking**                                                                                                                     NC                                \<0.001
  **    Yes**                                                  425 (68.8)                         NA                                      354 (65.5)   285 (51.8)   
  **    No**                                                   192 (31.2)                         NA                                      186 (34.4)   265 (48.2)   
  **Drinking**                                                                                                                    NC                                0.001
  **    Yes**                                                  411 (66.6)                         NA                                      300 (55.6)   251 (45.6)   
  **    No**                                                   206 (33.4)                         NA                                      240 (44.4)   299 (54.4)   

Abbreviations: NA, not available; NC, not calculated; ESCC, esophageal squamous cell carcinoma.

^1^Two-sided χ^2^ test.

^2^The median ages of the cases in the Hangzhou and Jinan populations were 62 and 56 years old, respectively.

10.1371/journal.pone.0127304.t002

###### Allele frequency distribution between the ESCC and control populations.

![](pone.0127304.t002){#pone.0127304.t002g}

  SNP name                                            Gene locus   Location    Function         Major/major allele   Major/minor allele   Minor/minor allele   No. of Major/major alleles in cases   No. of Major/minor alleles in cases   No. of Minor/minor alleles in cases   No. of Major/major alleles in controls   No. of Major/minor alleles in controls   No. of Minor/minor alleles in controls   X^2^ test (Hardy-Weinberg test for controls)   P value ((Hardy-Weinberg test for controls))   *P* (Fisher's test)
  --------------------------------------------------- ------------ ----------- ---------------- -------------------- -------------------- -------------------- ------------------------------------- ------------------------------------- ------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------
  **rs3805322**                                       ADH4         100056998   Intron region    AA                   AG                   GG                   236                                   256                                   123                                   125                                      246                                      141                                      0.744                                          0.689                                          **0.000**
  **rs4822983**                                       CHEK2        28719078    Intron region    CC                   CT                   TT                   358                                   226                                   32                                    324                                      166                                      23                                       0.087                                          0.957                                          0.225
  **rs10082466**                                      MBL2         52766862    3\'-UTR          AA                   AG                   GG                   437                                   161                                   15                                    369                                      147                                      13                                       0.621                                          0.733                                          0.844
  **rs1152620**                                       MALAT1       65489858    N/A              AA                   AG                   GG                   188                                   120                                   303                                   149                                      112                                      267                                      161.733                                        \<0.001                                        0.6
  **rs11548103**                                      S100A14      52766862    3\'-UTR          GG                   AG                   AA                   49                                    286                                   278                                   58                                       231                                      239                                      0.038                                          0.981                                          0.198
  **rs11716316**                                      ABI3BP       100764451   Intron region    AA                   AC                   CC                   188                                   138                                   286                                   150                                      117                                      262                                      152.489                                        \<0.001                                        0.6
  **rs9327870**                                       ABI3BP       102667853   N/A              TT                   TC                   CC                   186                                   258                                   85                                    218                                      281                                      115                                      2.079                                          0.353                                          0.426
  **rs12904**                                         EFNA1        155134221   Near Gene-5      AA                   AG                   GG                   451                                   152                                   11                                    393                                      125                                      11                                       0.082                                          0.959                                          0.862
  **rs1321311**                                       CDKN1A       36655123    N/A              GG                   GT                   TT                   425                                   166                                   16                                    364                                      146                                      16                                       0.085                                          0.958                                          0.901
  **rs17618244**                                      KLB          39446909    Missense         GG                   AG                   AA                   415                                   175                                   23                                    372                                      139                                      18                                       1.234                                          0.54                                           0.634
  **rs2073498**                                       RASSF1A      50332115    Missense         CC                   CA                   AA                   530                                   81                                    4                                     461                                      64                                       5                                        2.614                                          0.271                                          0.74
  **rs2114358**                                       miR-1206     128008933   Intron region    TT                   TC                   CC                   314                                   181                                   32                                    339                                      238                                      37                                       0.315                                          0.854                                          0.194
  **rs2285947**                                       DNAH11       21544470    Intron region    GG                   GA                   AA                   263                                   284                                   66                                    232                                      235                                      58                                       0.017                                          0.991                                          0.869
  **rs351855[\*](#t002fn002){ref-type="table-fn"}**   FGFR         177093242   Missense         TT                   CT                   CC                   402                                   5                                     191                                   334                                      14                                       146                                      430.686                                        \<0.001                                        **0.035**
  **rs4072037**                                       MUC1         155192276   Cds-synonymous   AA                   AG                   GG                   383                                   127                                   15                                    441                                      150                                      17                                       0.945                                          0.623                                          0.982
  **rs550894**                                        miR-612      65444469    ncRNA            GG                   GT                   TT                   342                                   238                                   31                                    282                                      208                                      35                                       0.163                                          0.922                                          0.466
  **rs699517**                                        TYMS         673016      3\'-UTR          TT                   CT                   CC                   259                                   287                                   67                                    236                                      240                                      53                                       0.499                                          0.779                                          0.698
  **rs8191664**                                       NEIL2        11786044    Missense         GG                   GT                   TT                   400                                   191                                   22                                    355                                      148                                      25                                       3.382                                          0.184                                          0.431

Abbreviations: ESCC, esophageal squamous cell carcinoma; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

\* Because the number of heterozygous alleles was too small, the P values for comparisons of major/major allele vs. major/minor allele vs. minor/minor allele were not sufficiently persuasive. The comparisons of TT+CT versus CC or TT versus CT+CC were not significant. Thus, we did not further evaluate this SNP.

We genotyped 18 selected SNPs in 17 genes for all 617 ESCC patients and 534 control subjects in the discovery arm (Hangzhou). The location and potential effects of these 18 SNPs, some of which cause amino acid substitutions in the proteins, are listed in **[Table 2](#pone.0127304.t002){ref-type="table"}**. The genotype frequencies of rs3805322 (*ADH4*) polymorphisms were significantly different between cases and controls (*P* \< 0.001, **[Table 2](#pone.0127304.t002){ref-type="table"}**). Sixteen SNPs in 15 genes, including *CHEK2*, *MBL2*, *MALAT1*, and *ABI3BP*, showed no significantly different allele frequency distributions between ESCC patients and control subjects based on Fisher's exact test (**[Table 2](#pone.0127304.t002){ref-type="table"}**). Unconditional univariate logistic regression analysis revealed a significantly increased risk of developing ESCC in subjects with the AA genotype for rs3805322 (*ADH4*) compared with those with the AG (OR 1.19, 95% CI 0.89--1.61) or GG (OR 2.16, 95% CI 1.56--3.00) genotypes. Similar results were obtained using dominant or recessive models, which produced respective ORs of 1.95 (95% CI 1.50--2.52, *P* \< 0.001) and 1.52 (95% CI 1.15--2.00, *P* = 0.003). Using the dominant model (CC vs. CT+TT), the CC genotype of rs4822983 had a marginally significant protective effect compared to the CT and TT genotypes (OR 0.81, 95% CI 0.64--1.03, *P* = 0.085). Similar results were observed for the two SNPs (rs3805322 and rs4822983) by multivariate logistic regression analysis, which was adjusted for environmental factors such as smoking and drinking (**[Table 3](#pone.0127304.t003){ref-type="table"}**).

10.1371/journal.pone.0127304.t003

###### Genotype frequencies of rs3805322 (ADH4) and rs4822983 (CHEK2) among cases and controls and their association with ESCC risk.

![](pone.0127304.t003){#pone.0127304.t003g}

  Genotype        Hangzhou case-control set   Jinan case-control set   All patients                                                                                                                        
  --------------- --------------------------- ------------------------ ------------------- --------- ------------ ------------ ------------------- --------- ------------ ------------ ------------------- ---------
  ***ADH4***      *n* = 615                   *n* = 512                                    \<0.001   *n* = 540    *n* = 550                        \<0.001   *n* = 1155   *n* = 1062                       \<0.001
  **rs3805322**                                                                                                                                                                                            
  **GG**          123 (20.0)                  141 (27.5)               1.00 (Reference)              117 (21.7)   150 (27.3)   1.00 (Reference)              240 (20.7)   291 (27.4)   1.00 (Reference)    
  **AG**          256 (41.6)                  246 (48.0)               2.20 (1.57--3.02)   \<0.001   220 (40.7)   261 (47.5)   1.86 (1.33--2.59)   \<0.001   476 (41.2)   507 (47.7)   1.13 (0.92--1.40)   0.248
  **AA**          236 (38.4)                  125 (24.4)               1.18 (0.88--1.59)   0.276     203 (37.6)   139 (25.3)   1.10 (0.81--1.49)   0.559     439 (38.1)   264 (24.8)   2.01 (1.60--2.53)   \<0.001
  ***CHEK2***     *n* = 616                   *n* = 513                                    0.089     *n* = 540    *n* = 550                        0.064     n = 1155     n = 1062                         0.011
  **rs4822983**                                                                                                                                                                                            
  **CC**          358 (58.1)                  324 (63.2)               1.00 (Reference)              224 (41.5)   350 (63.6)   1.00 (Reference)              582 (50.3)   674 (63.4)   1.00 (Reference)    
  **CT+TT**       258 (41.9)                  189 (36.8)               0.81 (0.63--1.03)             316 (58.5)   200 (36.4)   0.79 (0.61--1.01)             574 (49.7)   389 (36.6)   0.80 (0.67--0.95)   

Abbreviations: ESCC, esophageal squamous cell carcinoma; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

^1^ Multivariate logistic regression was used to evaluate the data adjusted for numerous variables, including age, sex, and smoking and drinking status.

The association of ESCC risk with these two SNPs (rs3805322 and rs4822983) was further validated in an independent case-control set (Jinan). Individuals with the *ADH4* rs3805322 AA or AG genotypes had ORs of 1.10 (95% CI = 0.81--1.49, *P* \< 0.001) or 1.86 (95% CI = 1.33--2.59, *P* = 0.559), respectively, for developing ESCC compared with those with the GG genotype. *CHEK2* rs4822983 CC carriers showed a marginally significantly decreased ESCC risk compared with those harboring the CT and TT genotypes in the Jinan population (95% CI = 0.61--1.01, *P* = 0.064) (**[Table 3](#pone.0127304.t003){ref-type="table"}**). The results became more significant when the two population sets were combined (**[Table 3](#pone.0127304.t003){ref-type="table"}**).

Because of the key roles of *ADH4* in ethanol metabolism and of *CHEK2* in DNA damage repair, these two SNPs were further examined by stratifying the subjects in the Jinan cohort by smoking status and alcohol drinking history (**[Table 4](#pone.0127304.t004){ref-type="table"}**). Interestingly, we found no significant association between the *ADH4* rs3805322 genotypes and ESCC risk among the subgroups of either smokers or non-smokers (**[Table 4](#pone.0127304.t004){ref-type="table"}**). There was a significant association between *ADH4* rs3805322 genotype and ESCC risk among alcohol drinkers (OR 2.59, 95% CI 1.76--3.84). However, there was no statistically significant association between the *CHEK2* rs4822983 genotype and ESCC risk. In addition, the gene-environment interactions between the two SNPs (*ADH4* rs3805322 and *CHEK2* rs4822983) and smoking or drinking were evaluated using SPSS. No evidence of interaction existed between the two SNPs and smoking or drinking in the Jinan cohort (**[Table 4](#pone.0127304.t004){ref-type="table"}**).

10.1371/journal.pone.0127304.t004

###### Risk of ESCC associated with the rs3805322 (ADH4) and rs4822983 (CHEK2) SNPs by smoking status and drinking history in the Jinan set.

![](pone.0127304.t004){#pone.0127304.t004g}

  Variable              *ADH4* rs3805322             *P* ~interaction~ [^2^](#t004fn003){ref-type="table-fn"}   *CHEK2* rs4822983           *P* ~interaction~ [^2^](#t004fn003){ref-type="table-fn"}                                         
  --------------------- ------------------ --------- ---------------------------------------------------------- ------------------- ------- ---------------------------------------------------------- --------- ------------------- ------- -------
  **Smoking status**                                                                                                                0.939                                                                                                    0.366
      **No**            112/169            74/96     0.86 (0.58--1.27)                                          0.443                       143/197                                                    97/102    0.76 (0.54--1.09)   0.132   
      **Yes**           204/181            104/150   0.78 (0.57--1.08)                                          0.131                       173/153                                                    127/98    0.87 (0.62--1.23)   0.434   
  **Drinking status**                                                                                                               0.085                                                                                                    0.302
      **No**            87/90              153/209   1.32 (0.92--1.90)                                          0.131                       112/169                                                    74/96     0.86 (0.58--1.27)   0.443   
      **Yes**           116/49             184/202   2.59 (1.76--3.84)                                          \<0.001                     204/181                                                    150/104   0.78 (0.57--1.08)   0.131   

Abbreviations: ESCC, esophageal squamous cell carcinoma; SNP, single nucleotide polymorphism; No., Number; OR, odds ratio; CI, confidence interval.

^1^ Logistic regression was used to evaluate the data adjusted for numerous variables, including age, sex, and smoking and drinking status.

^2^ The multiplicative interaction term was used to calculate *P* values for gene-environment interactions

Discussion {#sec011}
==========

Alcohol drinking is one of the most important modifiable lifestyle factors affecting EC, and alcohol metabolism has been suggested to play a central role in esophageal carcinogenesis \[[@pone.0127304.ref019]\]. Alcohol dehydrogenase enzymes (ADHs), which oxidize alcohol to acetaldehyde, are the most important and representative alcohol-metabolizing enzymes \[[@pone.0127304.ref020]\].

*ADH4* is a key member of the ADH family of proteins encoded by seven ADH genes, *ADH1A*, *ADH1B*, *ADH1C*, *ADH5*, *ADH4*, *ADH6*, and *ADH7* \[[@pone.0127304.ref021]\]. *ADH4* exhibits the highest catalytic efficiency in the human ADH family; it may account for as much as 40% of the total ethanol oxidation rate at intoxicating levels of alcohol. The association between EC and polymorphisms in some of these *ADH* genes, including rs1229984 (*ADH1B*), rs698 (*ADH1C*), rs17028973 (*ADH7*), and rs671 (*ALDH2*), has been investigated \[[@pone.0127304.ref008], [@pone.0127304.ref022]--[@pone.0127304.ref026]\].

In our study, we examined the association between 18 selected SNPs in 17 cancer-related genes and the risk of developing ESCC in a two Chinese populations. We found that patients with the AA genotype of rs3805322 (*ADH4*) had a significantly increased risk of developing ESCC compared with those with the AG or GG genotypes in our discovery dataset. Then, we successfully validated this result in a validation dataset (Jinan). In a matched case-control study including 585 patients with upper aerodigestive tract cancer and 1,170 non-cancer outpatients, Oze *et al*.\[[@pone.0127304.ref011]\] determined that compared with other genotypes, the GG genotype of *ADH4* rs3805322 was associated with an increased risk of upper aerodigestive tract cancer in per-allele, dominant, and recessive models. However, this previous study, which was conducted in a Japanese population, only included 265 EC patients. The results of our study, which included a total of 1155 ESCC patients and 1062 controls, are inconsistent with this report \[[@pone.0127304.ref011]\].

Among DNA repair genes, *CHEK2* (also known as Chk2 or Cds1) is a checkpoint kinase and transducer of cellular responses to DNA damage \[[@pone.0127304.ref027], [@pone.0127304.ref028]\]. Increasing evidence suggests that *CHEK2* plays an important role in DNA damage signaling networks. In the current study, we observed that the CC genotype of *CHEK2* rs4822983 showed a marginally significantly decreased ESCC risk compared with the CT and TT genotypes. When we combined the two groups, the significance increased. The results of our study are consistent with those of a genome-wide association study (GWAS) conducted by Wu *et al*. \[[@pone.0127304.ref029]\]. However, there was no interaction between the two polymorphisms (*ADH4* rs3805322 and *CHEK2* rs4822983) and drinking and smoking in terms of ESCC susceptibility.

Potential limitations of this study should be considered. First, this was a moderately sized case-control study with a total of more than 1,000 cases. The statistical power may be limited because of the sample size. Thus, it is important that the observed associations are validated in a larger study. Second, this was a hospital-based study; therefore, selection bias may be unavoidable. Third, data on smoking and drinking status were unknown in the Hangzhou case-control set and were therefore not adjusted for in the logistic regression models. A population-based study is needed to further validate our findings.

Conclusions {#sec012}
===========

The current study provides substantial evidence that genetic polymorphisms of rs3805322 in the *ADH4* gene may be associated with an increased risk of developing ESCC in two Chinese Han populations. Polymorphisms in *ADH4* rs3805322 influence susceptibility to ESCC in different genetic models of allele-dose effects and recessive effects. Future studies to address the biological function of these polymorphisms in the development of ESCC are warranted.
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